418 related articles for article (PubMed ID: 22128886)
1. Characterization of clinical strains of Aspergillus terreus complex: molecular identification and antifungal susceptibility to azoles and amphotericin B.
Escribano P; Peláez T; Recio S; Bouza E; Guinea J
Clin Microbiol Infect; 2012 Feb; 18(2):E24-6. PubMed ID: 22128886
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.
Wang HC; Hsieh MI; Choi PC; Wu CJ
J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30093391
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of amphotericin B, terbinafine, and azole drugs against clinical and environmental isolates of Aspergillus terreus sensu stricto.
Fernández MS; Rojas FD; Cattana ME; Sosa Mde L; Iovannitti CA; Lass-Flörl C; Giusiano GE
Antimicrob Agents Chemother; 2015; 59(6):3619-22. PubMed ID: 25824228
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
Kaya AD; Kiraz N
Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp.
Martín-Mazuelos E; Pemán J; Valverde A; Chaves M; Serrano MC; Cantón E
J Antimicrob Chemother; 2003 Sep; 52(3):365-70. PubMed ID: 12917236
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies.
Colozza C; Posteraro B; Santilli S; De Carolis E; Sanguinetti M; Girmenia C
Int J Antimicrob Agents; 2012 May; 39(5):440-3. PubMed ID: 22429723
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of nine antifungal agents against clinical isolates of Aspergillus calidoustus.
Alastruey-Izquierdo A; Cuesta I; Houbraken J; Cuenca-Estrella M; Monzón A; Rodriguez-Tudela JL
Med Mycol; 2010 Feb; 48(1):97-102. PubMed ID: 19296366
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species.
Misra R; Malik A; Singhal S
Indian J Pathol Microbiol; 2011; 54(1):112-6. PubMed ID: 21393890
[TBL] [Abstract][Full Text] [Related]
11. Aspergillus citrinoterreus, a new species of section Terrei isolated from samples of patients with nonhematological predisposing conditions.
Guinea J; Sandoval-Denis M; Escribano P; Peláez T; Guarro J; Bouza E
J Clin Microbiol; 2015 Feb; 53(2):611-7. PubMed ID: 25502530
[TBL] [Abstract][Full Text] [Related]
12. Multilocus Phylogeny and Antifungal Susceptibility of Aspergillus Section Circumdati from Clinical Samples and Description of A. pseudosclerotiorum sp. nov.
Siqueira JP; Sutton DA; Gené J; García D; Wiederhold N; Peterson SW; Guarro J
J Clin Microbiol; 2017 Mar; 55(3):947-958. PubMed ID: 28053212
[TBL] [Abstract][Full Text] [Related]
13. In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex.
Vaezi A; Fakhim H; Arastehfar A; Shokohi T; Hedayati MT; Khodavaisy S; Rezaei-Matehkolaei A; Badiee P; Hagen F; Lass-Flörl C; Dannaoui E; Meis JF; Badali H
Mycoses; 2018 Feb; 61(2):134-142. PubMed ID: 29064123
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Activities of Five Antifungal Drugs Against Opportunistic Agents of Aspergillus Nigri Complex.
Badali H; Fakhim H; Zarei F; Nabili M; Vaezi A; Poorzad N; Dolatabadi S; Mirhendi H
Mycopathologia; 2016 Apr; 181(3-4):235-40. PubMed ID: 26615417
[TBL] [Abstract][Full Text] [Related]
15. Molecular epidemiology and antifungal susceptibility of Candida parapsilosis sensu stricto, Candida orthopsilosis, and Candida metapsilosis in Taiwan.
Chen YC; Lin YH; Chen KW; Lii J; Teng HJ; Li SY
Diagn Microbiol Infect Dis; 2010 Nov; 68(3):284-92. PubMed ID: 20851551
[TBL] [Abstract][Full Text] [Related]
16. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp.
Gomez-Lopez A; Garcia-Effron G; Mellado E; Monzon A; Rodriguez-Tudela JL; Cuenca-Estrella M
Antimicrob Agents Chemother; 2003 Oct; 47(10):3085-8. PubMed ID: 14506013
[TBL] [Abstract][Full Text] [Related]
18. Isolation of Aspergillus udagawae from a fatal case of feline orbital aspergillosis.
Kano R; Itamoto K; Okuda M; Inokuma H; Hasegawa A; Balajee SA
Mycoses; 2008 Jul; 51(4):360-1. PubMed ID: 18855848
[TBL] [Abstract][Full Text] [Related]
19. Molecular identification and amphotericin B susceptibility testing of clinical isolates of Aspergillus from 11 hospitals in Korea.
Heo MS; Shin JH; Choi MJ; Park YJ; Lee HS; Koo SH; Lee WG; Kim SH; Shin MG; Suh SP; Ryang DW
Ann Lab Med; 2015 Nov; 35(6):602-10. PubMed ID: 26354348
[TBL] [Abstract][Full Text] [Related]
20. Nonsporulating clinical isolate identified as Petromyces alliaceus (anamorph Aspergillus alliaceus) by morphological and sequence-based methods.
Balajee SA; Lindsley MD; Iqbal N; Ito J; Pappas PG; Brandt ME
J Clin Microbiol; 2007 Aug; 45(8):2701-3. PubMed ID: 17537938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
